You are viewing: Italy Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The Italy Leukapheresis Market was valued at $0.85 Million in 2026 and projected to reach to $1.2 Million by 2031, representing a compound annual growth rate of 7.0%. Italy's leukapheresis market is positioned for steady growth through 2031, driven by expanding cell therapy programs and improved patient access to advanced hematologic treatments.

Italy Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Italy Leukapheresis Market Trends and Insights

  • This growth trajectory reflects Italy's advancing healthcare infrastructure and increasing adoption of cell therapy technologies within the country's medical centers.
  • Italy's market expansion is driven by rising prevalence of hematologic malignancies and growing investment in apheresis equipment across Italian hospitals and specialized treatment facilities. The Italian leukapheresis market benefits from strong regulatory frameworks and established clinical protocols within Italy's healthcare system.
  • Between 2026 and 2031, Italy is expected to see enhanced demand for leukapheresis procedures as CAR-T cell therapies and other cellular immunotherapies gain clinical acceptance throughout the country.
  • Italy's position within the European healthcare landscape positions the nation as a key market for advanced blood cell separation technologies..

Key Market Statistics

  • CAGR (2026-2031) 7.0% CAGR
  • Market Size, 2026 ~USD 0.85 Million
  • Forecast, 2031 ~USD 1.2 Million
  • Country Italy

Italy Leukapheresis Market Overview

Market Size & Growth :

Italy's leukapheresis market is valued at $0.85 million in 2026 and is projected to reach $1.20 million by 2031, with a steady CAGR of 7.0%, outpacing several European peers.

Healthcare Infrastructure Advancement :

Italy's modernizing healthcare system and investment in specialized medical centers are enabling wider adoption of leukapheresis technologies across hematology and oncology departments.

Cell Therapy Adoption :

Increasing clinical adoption of CAR-T and other cell-based therapies in Italian hospitals is driving demand for advanced leukapheresis equipment and services.

Hematologic Disease Prevalence :

Rising incidence of hematologic malignancies and blood disorders in Italy's aging population is creating sustained demand for leukapheresis procedures and related technologies.

Italy Leukapheresis Market Dynamics

  • The country's healthcare system is increasingly integrating leukapheresis into standard protocols for leukemia, lymphoma, and emerging CAR-T therapies.
  • Investment in specialized treatment centers and growing clinical awareness among Italian physicians will support market expansion.
  • However, reimbursement challenges and regulatory complexities may moderate growth rates compared to larger European markets..

Related Ecosystem

Key Takeaways

  • Italy's leukapheresis market is valued at $0.85 million in 2026 and will reach $1.20 million by 2031.
  • Italy demonstrates a 7.0% CAGR, reflecting steady growth in cell therapy adoption across the country.
  • Italy's healthcare infrastructure supports increasing demand for advanced apheresis procedures and equipment.
  • Italy is positioned as a significant European market for leukapheresis driven by clinical innovation and regulatory support.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

Italy Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

ITALY: LEUKOPAKS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES11.5412.914.4516.2118.2320.5423.226.2612.7
CONTRACT RESEARCH ORGANIZATIONS1.541.681.832.012.212.432.692.9710.1
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES4.515.125.816.617.548.629.8711.3314.3
TOTAL17.5919.6922.0924.8427.9831.635.7640.5612.9

ITALY: LEUKAPHERESIS MARKET, BY END USER, 2024–2031

Segment20242025202620272028202920302031CAGR (%)
ACADEMIC & RESEARCH INSTITUTES0.840.910.971.051.131.211.311.417.7
BLOOD COMPONENT PROVIDERS & BLOOD CENTERS2.072.262.472.72.953.233.543.889.4
HOSPITALS & TRANSFUSION CENTERS2.172.352.552.762.993.253.533.848.5
PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES0.520.550.590.620.660.710.760.816.5
TOTAL5.616.076.587.127.738.49.139.938.6

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and consumable producers need Italy-specific market data to assess commercial opportunity, set pricing strategies, and plan distribution partnerships.
  • Pharmaceutical & Biotech Companies : Cell therapy developers require Italy market insights to understand patient populations, treatment adoption rates, and healthcare infrastructure readiness for CAR-T and similar therapies.
  • Healthcare Providers & Hospital Networks : Italian hospitals and treatment centers need market intelligence to justify capital investments in leukapheresis technology and plan service expansion for hematologic patients.
  • Investment & Private Equity Firms : Investors evaluating healthcare opportunities in Italy require detailed market sizing and growth forecasts to assess portfolio companies and identify acquisition targets in cell therapy.
  • Healthcare Consultants & Analysts : Strategy consultants and market researchers need Italy-specific data to support client advisory work, competitive benchmarking, and market entry recommendations.

Key Companies in the Italy Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Italy-Specific Market Sizing : Precise valuation of Italy's leukapheresis market with granular 2026-2031 forecasts enables accurate budgeting and resource allocation for market entry or expansion strategies.
  • Competitive Landscape Intelligence : Understand Italy's unique competitive dynamics, key players, and market positioning to identify partnership opportunities and differentiation strategies in this emerging segment.
  • Regulatory & Reimbursement Insights : Gain clarity on Italy-specific regulatory pathways, healthcare reimbursement structures, and pricing dynamics that directly impact market viability and profitability.
  • Growth Driver Analysis : Detailed assessment of Italy's aging population, disease prevalence trends, and healthcare infrastructure investments that are fueling leukapheresis market expansion.
  • Strategic Market Entry Planning : Actionable recommendations tailored to Italy's healthcare ecosystem, enabling informed go-to-market strategies and investment decisions for medical device and therapy providers.

Frequently asked questions

What is the current size of Italy's leukapheresis market?

Italy's leukapheresis market is estimated at $0.85 million in 2026.

What is the projected market size for Italy by 2031?

Italy's leukapheresis market is forecast to reach $1.20 million by 2031.

What is the CAGR for Italy's leukapheresis market?

Italy's leukapheresis market is expected to grow at a compound annual growth rate of 7.0% from 2026 to 2031.

What factors are driving growth in Italy's leukapheresis market?

Growth in Italy is driven by increasing prevalence of hematologic malignancies, adoption of CAR-T cell therapies, and investment in apheresis equipment within Italian healthcare facilities.

How does Italy's leukapheresis market compare to other European countries?

Italy represents a significant European market for leukapheresis with established healthcare infrastructure and regulatory frameworks supporting cell therapy adoption.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status